Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Future Market Size Estimation For The Generative Artificial Intelligence (AI) In Drug Discovery Market Covering 2025–2034?
The market size for generative artificial intelligence (AI) in drug discovery has witnessed significant expansion in recent years. It is projected to grow from $0.19 billion in 2024 to $0.25 billion in 2025, achieving a compound annual growth rate (CAGR) of 30.6%. This historical growth stems from factors such as the rising prevalence of chronic diseases, advancements in new drug discoveries and clinical trials, initiatives supporting AI integration into healthcare and drug development, the growth of biotech industries, and increasing governmental support.
The market for generative artificial intelligence (AI) in drug discovery is projected to experience substantial expansion in the coming years. This market is anticipated to reach ” $0.7 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 28.8%. Several factors contribute to this growth during the forecast period, including the demand for affordable drug discovery methods, which fuels the adoption of generative AI, an increase in partnerships among market participants, advancements in computational capabilities, the convergence of generative AI with other nascent technologies, and accelerated drug development processes. Key trends anticipated in this period encompass sophisticated technological advancements, the merging of generative AI with experimental biology, the use of high-throughput screening to expedite drug discovery pipelines, the creation of AI-powered platforms for drug repurposing, and a growing embrace of cloud-based AI solutions to facilitate collaborative drug discovery initiatives.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16067&type=smp
What Are The Main Drivers Boosting The Generative Artificial Intelligence (AI) In Drug Discovery Industry’s Expansion?
An increase in clinical trials is anticipated to boost the expansion of generative AI in the drug discovery market. These trials enlist human participants to evaluate the safety and efficacy of novel medical interventions or processes, with the goal of collecting scientific information regarding their appropriateness for human application. The growing volume of clinical trials is mainly due to progress in medical research, a higher prevalence of diseases, evolving regulations, the worldwide expansion of clinical research, enhanced patient advocacy and understanding, competitive industry dynamics, technological innovations, and available financial support. Information derived from clinical trials empowers generative AI models, accelerating the drug discovery process through the prediction of molecular interactions and the design of novel compounds. This collaborative effect facilitates personalized medicine, enhances the effectiveness of treatments, leads to better patient results, and transforms the pharmaceutical sector. For example, data from ClinicalTrials.gov, a US-based clinical trial registry, shows that as of the close of 2023, a total of 477,234 clinical trials were registered worldwide, representing a rise from the 437,512 trials recorded in 2022. Consequently, the expanding volume of clinical trials is fueling the development of generative AI in the drug discovery market.
What Are The Leading Segments Analyzed In The Generative Artificial Intelligence (AI) In Drug Discovery Market?
The generative artificial intelligence (AI) in drug discoverymarket covered in this report is segmented –
1) By Type: Small Molecule; Large Molecule
2) By Technology: Deep Learning; Machine Learning; Reinforcement Learning; Molecular Docking; Quantum Computing
3) By End-User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutions; Contract Research Organizations (CROs); Other End-Users
Subsegments:
1) By Small Molecule: Drug Design And Optimization; Lead Discovery And Identification; Toxicology Prediction; Molecular Property Prediction; ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction
2) By Large Molecule: Protein Structure Prediction; Antibody Design; Biologics Optimization; Peptide Design; Biopharmaceutical Discovery And Optimization
What Long-Term Trends Will Shape The Future Growth Of The Generative Artificial Intelligence (AI) In Drug Discovery Industry?
Leading companies engaged in generative AI within the drug discovery market are developing sophisticated AI-powered instruments to expedite drug discovery processes. These AI tools accelerate drug development by optimizing drug discovery, design, and clinical trials through the application of predictive analytics and machine learning. They boost efficiency in areas such as target identification, compound screening (including virtual screening using AI), preclinical development, regulatory compliance, and manufacturing operations. For instance, in May 2023, Google Cloud, a US-based cloud computing service provided by Google, launched two innovative AI-driven solutions. These solutions, the Target and Lead Identification Suite and the Multiomics Suite, are designed to enhance drug discovery and precision medicine across biotech, pharmaceutical, and public sector organizations. The Target and Lead Identification Suite aids researchers in understanding amino acid functions and predicting protein structures, while the Multiomics Suite accelerates the analysis and comprehension of genomic data, simplifying the development of personalized treatments.
Which Key Market Players Are Investing In Expansion And Innovation Of Generative Artificial Intelligence (AI) In Drug Discovery Market?
Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrödinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc., DeepMatter Group Limited, Variational AI Inc
Download The Full Report For Exclusive Market Findings:
Which Region Shows The Highest Potential For Future Expansion In The Generative Artificial Intelligence (AI) In Drug Discovery Market?
North America was the largest region in the generative AI in drug discovery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Generative Artificial Intelligence (AI) In Drug Discovery Market Report:
https://www.thebusinessresearchcompany.com/customise?id=16067&type=smp
Browse Through More Reports Similar to the Global Generative Artificial Intelligence (AI) In Drug Discovery Market 2025, By The Business Research Company
Generative Artificial Intelligence Ai In Sports Global Market Report 2025
Generative Artificial Intelligence In Development And Operations Devops Global Market Report 2025
Artificial Intelligence In Drug Discovery Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model